Evidence map›Paper›PMID 39329715›Full record

ArticleCells2024

Lauren S Strathearn, Lindsay C Spender, Christina Schoenherr, Susan Mason, Ruaridh Edwards, Karen Blyth, Gareth J Inman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lauren S StrathearnDivision of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.
Lindsay C SpenderDivision of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.ORCID 0009-0005-2936-6828
Christina SchoenherrCancer Research UK Scotland Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK.ORCID 0000-0002-0983-6168
Susan MasonCancer Research UK Scotland Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK.
Ruaridh EdwardsDivision of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.ORCID 0000-0001-7456-881X
Karen BlythCancer Research UK Scotland Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK.ORCID 0000-0002-9304-439X
Gareth J InmanDivision of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.ORCID 0000-0002-6264-4253

Funding

Cancer Research UK A29802
6 · The paper itself

Abstract

Transforming Growth Factor-β (TGF-β) can have both tumour-promoting and tumour-suppressing activity in breast cancer. Elucidating the key downstream mediators of pro-tumorigenic TGF-β signalling in this context could potentially give rise to new therapeutic opportunities and/or identify biomarkers for anti-TGF-β directed therapy. Here, we identify

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticSmad3 ProteinTransforming Growth Factor betaAnimalsCell Line, TumorCell MovementFemaleHumansMicePrognosisSignal TransductionSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor betabreast carcinomaC1orf106INAVATGF-β

Identifiers

PMID39329715
PMCPMC11429573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.